<DOC>
	<DOC>NCT02474407</DOC>
	<brief_summary>This is a multi-center, open-label, crossover, pharmacokinetic, bioavailability study involving adolescents and adults with refractory (drug-resistant) epilepsy</brief_summary>
	<brief_title>A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)</brief_title>
	<detailed_description>To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<mesh_term>Diazepam</mesh_term>
	<criteria>Diagnosis of refractory epilepsy Body weight 26 to 111 kilogram (kg) inclusive Other inclusion criteria apply Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product Female subject who is pregnant, breastfeeding, or planning to become pregnant Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Seizures</keyword>
	<keyword>Epilepsy</keyword>
</DOC>